Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

    - Results from a randomized Phase IIb trial reported at 2009 ASCO Annual
    Meeting -

MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced Stage III/IVa head and neck cancer conducted by Reddy BK et al (Kidwai Memorial Institute of Oncology, Bangalore, India), were presented in a poster at the 2009 ASCO Annual Meeting. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab. The authors further conclude that this trial is the first randomized study in head and neck cancer to their knowledge that challenges the adopted tenet that the efficacy of EGFR inhibitors is linked to the toxicity of the class.

"These data are further evidence of the unsupported extrapolation to the class of the toxicity/benefit correlation in the marketed EGFR drugs. The trial data demonstrate that patients have the prospect of equivalent clinical benefit from nimotuzumab as from the rest of the class without the physical, emotional and financial costs that result from the numerous and severe toxicities of Erbitux(R) which are a consequence of the demonstrable inability of that drug to discriminate between healthy cells and tumor cells," said David Allan, Chairman and CEO of YM BioSciences. "We expect that, as the numerous randomized trials currently ongoing worldwide with nimotuzumab re
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... DALLAS , July 10, 2014  Kainos Capital, ... consumer brands, today announced that it has acquired the ... stake in the business. Terms of the transaction were ... loss and meal replacement business that markets ready-to-drink shakes, ... North America and in the ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Monogram announces availability of HERmark and HER1 and HER3 ... Assays ... June 2 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... on HERmark(TM),the company,s novel oncology assay, as a means ...
... (TSH),Canada,s largest urban community hospital, has selected Chyma(TM) ... The,implementation of Chyma(TM) for their team of more ... departments at the two hospital campuses and will,soon ... "Chyma(TM) reflects the commitment of the Scarborough ...
... 2 The following release was,issued today by Thomas P. ... the New York State Common Retirement Fund, the Lead Plaintiff,in ... UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA ... MCK ) SECURITIES LITIGATION, Master File No. 99-CV-20743 ...
Cached Biology Technology:Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 2Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 3Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 4Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 5Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 6Canada's Largest Urban Community Hospital Chooses Chyma(TM) On-Call Physician Scheduling Technology 2Notice of Initial Distribution of Net Settlement Funds 2Notice of Initial Distribution of Net Settlement Funds 3
(Date:7/11/2014)... Conservation Society shows that no-take zones in Belize ... as lobster, conch, and fish recover from overfishing, ... , The reporttitled "Review of the Benefits of ... from no-take areas around the world. The report ... expert in marine protected areas and fisheries management. ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... eastern New South Wales, Australia when NASA,s Aqua satellite ... on July 11 (12:35 p.m. local time/11:35 p.m. EDT ... South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) ... and spotted smoke (light brown) from various fires. Actively ... in red. , The New South Wales, Australia Government ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... find your location, the brain has an internal system for ... surroundings. A new study from researchers at Princeton University ... study, published in the journal Nature , indicates that ... activity up and down by working together in a collective ...
... , , , , , , ... AUDIO: Kathryn E. Henderson, PhD, Director of School and Community Initiatives at the Yale Rudd Center, talks about the first ... for more information. , , , , ... , , , , , , , ...
... 6, 2013) -- Working with a multidisciplinary consortium of ... critical information to identify CALHM1, a channel in the ... in the process of sweet, bitter, and umami (savory) ... reach the tongue, they activate taste receptors in specialized ...
Cached Biology News:Researchers discover workings of brain's 'GPS system' 2Stronger support needed for healthy beverage practices in child care 2Stronger support needed for healthy beverage practices in child care 3Stronger support needed for healthy beverage practices in child care 4Monell scientists help identify a missing link in taste perception 2
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Proliferin (C-14)...
... your ValveBank system! Program your valve ... computer using graphic 'click-and-drag' timebars. Save and ... program listings, then download your programs into ... EasyCode is used for programming before -- ...
Biology Products: